Goodwin Procter advised MOMA Therapeutics on the deal. MOMA Therapeutics announced its completion of a $150 million Series B Financing. MOMA Therapeutics is a biopharmaceutical company […]
MOMA Therapeutics’ $150 Million Series B Financing
Adicet Bio’s $100.6 Million Rights Offering
Goodwin Procter advised Adicet Bio, Inc. on the deal. Adicet Bio, Inc. (Nasdaq: ACET) announced its underwritten public offering of 7,187,500 shares of its common stock, including […]
Intellia Therapeutics’ $690 Million Underwritten Public Offering
Goodwin Procter advised Intellia Therapeutics on the deal. Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever […]
Nimbus Therapeutics’ $105 Million Private Financing Round
Goodwin Procter LLP advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced the closing of a $105 million private financing round which was led by BVF Partners […]
ElevateBio’s $525 Million Series C Financing
Goodwin Procter LLP advised ElevateBio on the deal. ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced it […]
Adicet Bio, Inc.’s $137.5 Million Rights Offering
Goodwin Procter LLP advised Adicet Bio, Inc. on the deal. Adicet Bio, Inc. (Nasdaq: ACET) announced its underwritten public offering of 10,575,513 shares of its common stock, […]